Higher Doses of Semaglutide Demonstrate Safe and Effective Weight Loss in Adults with Obesity
Clinical trials confirm that higher doses of semaglutide are safe and significantly more effective in promoting weight loss in adults with obesity, including those with type 2 diabetes.
Recent clinical trials have revealed that increasing the weekly dosage of semaglutide to 7.2 mg significantly enhances weight loss outcomes for adults living with obesity, including those with type 2 diabetes. These findings stem from two large-scale, international phase 3 studies, published in The Lancet Diabetes & Endocrinology, which evaluated the safety and efficacy of higher dose semaglutide.
In the studies, participants were randomly assigned to receive either the higher 7.2 mg dose, the currently approved 2.4 mg dose, or a placebo over a period of 72 weeks. All participants also received lifestyle guidance, such as dietary counseling and physical activity advice. Results showed that adults without diabetes taking the 7.2 mg dose lost an average of nearly 19% of their body weight, surpassing the 16% weight loss seen with the 2.4 mg dose and the 4% with placebo. Notably, approximately half of these participants lost 20% or more of their body weight, with about one-third achieving at least 25% reduction.
Participants experienced improvements in waist circumference, blood pressure, blood sugar levels, and cholesterol, reducing overall health risks related to obesity. For adults with obesity and T2D, the higher dose led to an average weight loss of 13%, compared to 10% with 2.4 mg and 3.9% with placebo. Additionally, there were significant gains in blood sugar control and waist size reduction.
Importantly, the studies confirmed that the higher dose was well tolerated and safe, with common side effects being gastrointestinal issues like nausea and diarrhea, which were manageable and temporary. No increase in severe adverse events or hypoglycemia was observed.
These promising results suggest that higher doses of semaglutide could become a valuable option for individuals struggling to lose weight with current treatments, helping to mitigate obesity-related health problems on a larger scale. However, further research is needed to assess long-term benefits and safety. Source: https://medicalxpress.com/news/2025-09-higher-doses-semaglutide-safely-weight.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
The Importance of Discussing Sexual Health After Gynecological Cancer Treatment
Open communication about sexual health post-gynecological cancer treatment is essential for survivors' well-being. Learn how healthcare providers can support emotional and physical intimacy through respectful conversations.
Fetal Movements and Maternal-Baby Attachment: Insights from Recent Research
New research shows that fetal movements are strongly linked to the emotional bond between mother and baby, highlighting the importance of fetal activity in prenatal attachment and caregiving.
Artificial Intelligence Uncovers Hidden Signs of Parkinson's Disease Through Finger-Tapping Video Analysis
Cutting-edge AI technology analyzes finger-tapping videos to detect early signs of Parkinson's disease, enabling earlier diagnosis and intervention using simple video recordings.
New Insights into Glioblastoma: Cell Clustering May Influence Tumor Aggressiveness
New research uncovers how glioblastoma cell clustering influences tumor severity. Dispersed cells show higher plasticity and treatment resistance, offering potential new therapeutic targets.